The Logiq E9 Agile ultrasound system from GE Healthcare has a new complement of seven transducers and software improvements addressing cardiac, vascular and pediatric applications.
GE updates Logiq E9
The Logiq E9 Agile ultrasound system from GE Healthcare has a new complement of seven transducers and software improvements addressing cardiac, vascular and pediatric applications. The enhancements are part of GE’s Breakthrough 2010 upgrade.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.